Lilly’s Paying $1.1bn For Itch Advantage With Dermira’s Lebrikizumab
Executive Summary
Making a large acquisition heading into the JP Morgan Healthcare Conference for the second consecutive year, Lilly is buying Dermira and its Phase III atopic dermatitis drug lebrikizumab, setting up a competition with Sanofi’s Dupixent.
You may also be interested in...
BIO 2020 Notebook: Conversations On Rebates, Racism And Remote Working
News and views from day four of BIO Digital also include discussion of whether the pandemic is discouraging mega mergers.
BIO 2020 Notebook: Conversations On Rebates, Racism, And Remote Working
News and views from day four of BIO Digital also include discussion of whether the pandemic is discouraging mega mergers.
Biopharma Quarterly Dealmaking Statistics, Q1 2020
During Q1, biopharmas brought in an aggregate $13.8bn in financing. M&A value reached $6.9bn, the majority from Gilead Sciences $4.9bn purchase of immuno-oncology firm Forty Seven. Alliances fetched $35bn in potential deal value, dominated by many Big Pharma tie-ups led by a $4bn discovery and development collaboration between AstraZeneca and Silence Therapeutics for siRNA therapeutics.
Need a specific report? 1000+ reports available
Buy Reports